First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) - Townsend, William; Leong, Sarah; Tucker, David; Pottinger, Bryson; Paneesha, Shankara; El-Sharkawi, Dima; Eyre, Toby A.; Batten, Toby; Shah, Mittal; Cook, Sarah; Granger, David; O'Donovan, Kieran; et al. (Blood, 2022)